SMAD7 and cancer: SMAD7 is a key negative regulator of TGF-β signaling, it antagonizes TGF-β signaling through multiple mechanisms in the context of different cell types, and altered expression of SMAD7 is often associated with cancer, tissue fibrosis and inflammatory diseases (Miyazawa and Miyazono, 2017).